Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1/2 Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
NCT Number:
NCT04068896
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Bladder, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Ovary, Pancreas, Prostate, Rectum, Stomach
Study Objectives:
This is a multicenter, Phase 1a/1b, study consisting of 2 parts, with Part 1 the Phase 1a portion of the study and Part 2 the Phase 1b portion. The aim of the study is to evaluate the safety and tolerability, as well as to obtain preliminary evidence of antitumor activity and anti-CACS activity, of NGM120 monotherapy in subjects with select advanced solid tumors (Part 1) and of NGM120 in combination with gemcitabine and Abraxane for the management of metastatic pancreatic cancer (Part 2). Part 2 will start at the same time as Part 1 and run concurrently.
Study Documents
(MUSC NetID required for document access)